08:59 AM EST, 02/26/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Wednesday that an interim analysis of the phase 3 trial of its experimental therapy, camizestrant, combined with a cyclin-dependent kinase inhibitor showed statistically significant and clinically meaningful improvement in progression-free survival in certain breast cancer patients compared to standard of care.

Although key secondary endpoints such as time-to-second disease progression and overall survival were not fully mature, the combination therapy showed a trend toward improvement, the company said.

The drugmaker said the trial will continue to assess secondary endpoints as planned.